Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
about
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.Rho, a Fraction From Rhodiola crenulate, Ameliorates Hepatic Steatosis in Mice Models.Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo modelEmerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLDThiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin
P2860
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
@en
type
label
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
@en
prefLabel
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
@en
P2860
P1476
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
@en
P2093
Arun J Sanyal
Bubu A Banini
P2860
P304
P356
10.1097/MOG.0000000000000356
P577
2017-03-24T00:00:00Z